Immunoassay standardisation for "universal" influenza vaccines

Workshop report

Sophia Pavlova, Flavia D'Alessio, Sophie Houard, Edmond J. Remarque, Norbert Stockhofe, Othmar G. Engelhardt*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called universal influenza vaccines and to explore a path towards the standardisation of such assays. More than fifty experts from the global influenza vaccine research and development field met to initiate such discussion at a workshop co-organised by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health/National Institute of Allergy and Infectious Diseases, USA. The workshop audience agreed that it was not possible to establish a single immunoassay for "universal" influenza vaccines because the current approaches differ in the vaccines' nature and immunogenicity properties. Therefore, different scientific rationales for the immunoassay selection are required. To avoid dilution of efforts, the choice of the primary evaluation criteria (eg serological assays or T-cell assays) should drive the effort of harmonisation. However, at an early phase of clinical development, more efforts on exploratory assessments should be undertaken to better define the immune profile in response to immunisation with new vaccines. The workshop concluded that each laboratory should aim towards validation of the appropriate immunoassays used during the entire process of vaccine development from antigen discovery up to establishment of correlates of protection, including the different steps of quality control (eg potency assays), animal studies and human clinical development. Standardisation of the immunoassays is the ultimate goal, and there is a long way to go.

Original languageEnglish
Pages (from-to)194-201
JournalInfluenza and Other Respiratory Viruses
Volume11
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Influenza Vaccines
Immunoassay
Education
Vaccines
National Institute of Allergy and Infectious Diseases (U.S.)
National Institutes of Health (U.S.)
Human Development
European Union
Quality Control
Immunization
T-Lymphocytes
Antigens
Research

Keywords

  • Immunoassay
  • Influenza
  • Standardisation
  • Universal
  • Vaccine
  • Workshop

Cite this

Pavlova, Sophia ; D'Alessio, Flavia ; Houard, Sophie ; Remarque, Edmond J. ; Stockhofe, Norbert ; Engelhardt, Othmar G. / Immunoassay standardisation for "universal" influenza vaccines : Workshop report. In: Influenza and Other Respiratory Viruses. 2017 ; Vol. 11, No. 3. pp. 194-201.
@article{5f8eb1f681e8466f940bb0a9caf1340f,
title = "Immunoassay standardisation for {"}universal{"} influenza vaccines: Workshop report",
abstract = "The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called universal influenza vaccines and to explore a path towards the standardisation of such assays. More than fifty experts from the global influenza vaccine research and development field met to initiate such discussion at a workshop co-organised by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health/National Institute of Allergy and Infectious Diseases, USA. The workshop audience agreed that it was not possible to establish a single immunoassay for {"}universal{"} influenza vaccines because the current approaches differ in the vaccines' nature and immunogenicity properties. Therefore, different scientific rationales for the immunoassay selection are required. To avoid dilution of efforts, the choice of the primary evaluation criteria (eg serological assays or T-cell assays) should drive the effort of harmonisation. However, at an early phase of clinical development, more efforts on exploratory assessments should be undertaken to better define the immune profile in response to immunisation with new vaccines. The workshop concluded that each laboratory should aim towards validation of the appropriate immunoassays used during the entire process of vaccine development from antigen discovery up to establishment of correlates of protection, including the different steps of quality control (eg potency assays), animal studies and human clinical development. Standardisation of the immunoassays is the ultimate goal, and there is a long way to go.",
keywords = "Immunoassay, Influenza, Standardisation, Universal, Vaccine, Workshop",
author = "Sophia Pavlova and Flavia D'Alessio and Sophie Houard and Remarque, {Edmond J.} and Norbert Stockhofe and Engelhardt, {Othmar G.}",
year = "2017",
doi = "10.1111/irv.12445",
language = "English",
volume = "11",
pages = "194--201",
journal = "Influenza and Other Respiratory Viruses",
issn = "1750-2640",
publisher = "Wiley",
number = "3",

}

Immunoassay standardisation for "universal" influenza vaccines : Workshop report. / Pavlova, Sophia; D'Alessio, Flavia; Houard, Sophie; Remarque, Edmond J.; Stockhofe, Norbert; Engelhardt, Othmar G.

In: Influenza and Other Respiratory Viruses, Vol. 11, No. 3, 2017, p. 194-201.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Immunoassay standardisation for "universal" influenza vaccines

T2 - Workshop report

AU - Pavlova, Sophia

AU - D'Alessio, Flavia

AU - Houard, Sophie

AU - Remarque, Edmond J.

AU - Stockhofe, Norbert

AU - Engelhardt, Othmar G.

PY - 2017

Y1 - 2017

N2 - The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called universal influenza vaccines and to explore a path towards the standardisation of such assays. More than fifty experts from the global influenza vaccine research and development field met to initiate such discussion at a workshop co-organised by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health/National Institute of Allergy and Infectious Diseases, USA. The workshop audience agreed that it was not possible to establish a single immunoassay for "universal" influenza vaccines because the current approaches differ in the vaccines' nature and immunogenicity properties. Therefore, different scientific rationales for the immunoassay selection are required. To avoid dilution of efforts, the choice of the primary evaluation criteria (eg serological assays or T-cell assays) should drive the effort of harmonisation. However, at an early phase of clinical development, more efforts on exploratory assessments should be undertaken to better define the immune profile in response to immunisation with new vaccines. The workshop concluded that each laboratory should aim towards validation of the appropriate immunoassays used during the entire process of vaccine development from antigen discovery up to establishment of correlates of protection, including the different steps of quality control (eg potency assays), animal studies and human clinical development. Standardisation of the immunoassays is the ultimate goal, and there is a long way to go.

AB - The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called universal influenza vaccines and to explore a path towards the standardisation of such assays. More than fifty experts from the global influenza vaccine research and development field met to initiate such discussion at a workshop co-organised by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health/National Institute of Allergy and Infectious Diseases, USA. The workshop audience agreed that it was not possible to establish a single immunoassay for "universal" influenza vaccines because the current approaches differ in the vaccines' nature and immunogenicity properties. Therefore, different scientific rationales for the immunoassay selection are required. To avoid dilution of efforts, the choice of the primary evaluation criteria (eg serological assays or T-cell assays) should drive the effort of harmonisation. However, at an early phase of clinical development, more efforts on exploratory assessments should be undertaken to better define the immune profile in response to immunisation with new vaccines. The workshop concluded that each laboratory should aim towards validation of the appropriate immunoassays used during the entire process of vaccine development from antigen discovery up to establishment of correlates of protection, including the different steps of quality control (eg potency assays), animal studies and human clinical development. Standardisation of the immunoassays is the ultimate goal, and there is a long way to go.

KW - Immunoassay

KW - Influenza

KW - Standardisation

KW - Universal

KW - Vaccine

KW - Workshop

U2 - 10.1111/irv.12445

DO - 10.1111/irv.12445

M3 - Article

VL - 11

SP - 194

EP - 201

JO - Influenza and Other Respiratory Viruses

JF - Influenza and Other Respiratory Viruses

SN - 1750-2640

IS - 3

ER -